Genelabs Technologies

Genelabs Technologies

Biotechnology, Network BLVD, San Antonio, , 78249, Texas, 12500, United States, 51-200 Employees

genelabs.com

  • LinkedIn

phone no Phone Number: +18*********

Who is GENELABS TECHNOLOGIES

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E par...

Read More

map
  • 12500 Network BLVD, San Antonio, Texas, 78249, United States Headquarters: 12500 Network BLVD, San Antonio, Texas, 78249, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 8733 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GENELABS TECHNOLOGIES

Genelabs Technologies Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Genelabs Technologies

Answer: Genelabs Technologies's headquarters are located at Network BLVD, San Antonio, , 78249, Texas, 12500, United States

Answer: Genelabs Technologies's phone number is +18*********

Answer: Genelabs Technologies's official website is https://genelabs.com

Answer: Genelabs Technologies's revenue is $10 Million to $25 Million

Answer: Genelabs Technologies's SIC: 8733

Answer: Genelabs Technologies's NAICS: 325412

Answer: Genelabs Technologies has 51-200 employees

Answer: Genelabs Technologies is in Biotechnology

Answer: Genelabs Technologies contact info: Phone number: +18********* Website: https://genelabs.com

Answer: Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access